Analysts at BMO Capital Markets initiated coverage on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report issued on Monday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $15.00 price target on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 50.91% from the company’s previous close.

TRVI has been the topic of several other reports. Stifel Nicolaus began coverage on Trevi Therapeutics in a research note on Monday. They set a “buy” rating and a $20.00 price objective on the stock. Leerink Swann began coverage on Trevi Therapeutics in a research note on Monday. They set an “outperform” rating on the stock. Five equities research analysts have rated the stock with a buy rating, Trevi Therapeutics currently has an average rating of “Buy” and a consensus price target of $16.75.

Shares of NASDAQ:TRVI opened at $9.94 on Monday. Trevi Therapeutics has a 1-year low of $7.18 and a 1-year high of $10.62.

In other Trevi Therapeutics news, major shareholder Invest A/S Lundbeckfond bought 375,000 shares of the firm’s stock in a transaction dated Thursday, May 9th. The stock was purchased at an average cost of $10.00 per share, with a total value of $3,750,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Anne Vanlent bought 5,000 shares of the firm’s stock in a transaction dated Thursday, May 9th. The shares were acquired at an average cost of $10.00 per share, with a total value of $50,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 391,250 shares of company stock valued at $3,912,500.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

Further Reading: What is a Fibonacci Channel?

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.